Supplementary Figure 1: MLN7243 inhibits both UBA1 and UBA6. UBA1 and UBA6 form reducing agent-sensitive thioesters with ubiquitin. UBA6 also forms a thioester with the UBL protein FAT10. UBA6 but not UBA1 can transfer ubiquitin and FAT10 to the E2 enzyme UBE2Z/USE1 to form a UBE2Z thioester. (A) The indicated cells were treated with carrier (-) or 0.1μM MLN7243 (+) for 12 hours. Samples were analysed by western blotting. A primary antibody that recognises both isoforms of UBA1 was used. Slower mobility thioesters of UBA1, UBA6 and UBE2Z were detected in the absence of reducing agent (-DTT). The molecular weight of ubiquitin and FAT10 are 8 and 18 kDa respectively. The migration of the detected reducing agent-sensitive form of UBE2Z indicated that it corresponded to a ubiquitin-UBE2Z thioester. MLN7243 inhibited UBA1, UBA6 and UBE2Z-thioester formation. (B) SCCRDEBMet and SCCIC1 cell lines were treated with MLN7243 for 12 hours and analysed by western blotting. MLN7243 inhibited UBA6 and UBE2Z thioester formation in a dose-dependent manner. 
The proteolytic activities of the proteasome were assayed 8 hours after the addition of ixazomib. The results were expressed as a percentage of the activity with carrier alone. Values are the mean -/+ range of 2 independent experiments. Increased death of SCCRDEB4 cells resulting from a pulse of ixazomib exposure first occurred at ixazomib concentrations that strongly inhibit both the chymotrypsin and caspase-like activities of the proteasome.
Supplementary Figure 5:
A pulse of bortezomib has similar effects on the pattern of ubiquitination in bortezomibsensitive and bortezomib-resistant cSCC cells. The SCCIC1 cell line which is sensitive to a pulse of bortezomib and the paired metastatic SCCIC1Met cell line which is resistant to a pulse of bortezomib were treated with carrier or 0.1 μM bortezomib (BZ) for 8 hours. The cells were incubated in bortezomib-free medium for the indicated time after drug addition and analysed by western blotting for ubiquitin. The effect on the pattern of ubiquitination was similar in the cell lines: High molecular weight ubiquitin conjugates were accumulated after bortezomib addition and returned to basal after inhibitor removal at similar rates. Ubiquitinated histone H2A/H2B levels were reduced by bortezomib and returned to basal levels with similar kinetics. Figure 6 ) the rate of cell death was slow in SCCRDEBMet and SCCIC1Met cells.
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